药物肝损伤的潜在生物标志物循环miR-122的研究进展  

Progress in circulating miR-122 as potential biomarker for drug-induced liver injury

作　　者：王雁 汤纳平 马璟 

机构地区：[1]中国医药工业研究总院国家上海新药安全评价研究中心,上海201203

出　　处：《中国药理学与毒理学杂志》2013年第1期110-113,共4页Chinese Journal of Pharmacology and Toxicology

基　　金：国家十二五科技重大专项基金(2012ZX09505-001-003)~~

摘　　要：药物诱导的肝损伤是药物研发失败或退市的主要原因之一,而传统的肝损伤评价指标因为种种缺陷如缺乏特异性或灵敏性而不能为药物的肝毒性评价提供早期、及时和可靠的信号。循环微RNA-122(miR-122)因其在肝脏特异性表达、以及其高度的稳定性和灵敏性成为目前肝毒性评价指标的研究热点。本综述主要从特异性、稳定性和灵敏性3方面系统地阐述循环miR-122成为肝毒性生物标志物的应用潜力,并对下一步的研究工作进行探讨。Drug-induced liver injury （DILl） is one the cause of drug attrition during drug development and post-mar- keting drug withdrawal. Currently, the traditional biomarkers cannot meet the requirements of early detection of DILl during drug development for lack of sensitivity and specificity, miR-122 is an abundant, liver-specific microRNA and has recently been reported to be remarkably stable in plasma. Given its high stability, sensitivity and specificity, miR-122 has recently been thought of as a new potential biomarker for DILl. In this paper, the potential application of miR-122, as a biomarker of DILl, was systematically reviewed in terms of the specificity, stability and sensitivity of miR-122. The prospect of research was also discussed.

关 键 词：微RNAS MIR-122 生物标志物 肝 毒性作用 

分 类 号：R595.3[医药卫生—内科学]